Denali Therapeutics Inc. announced that Steve Krognes will transition from his role as Chief Financial Officer (CFO) and join the company's Board of Directors on May 1, 2022. Steve Krognes joined Denali in 2015 as the founding CFO, building and leading the finance team as well as supervising the IT and facilities functions. He has led successful financings for Denali, including the initial public offering in 2017, and has contributed significantly to the company's growth and strong financial position.

His extensive leadership experience in the biotech and pharmaceutical industry includes 12 years at Roche /Genentech, serving as CFO of Genentech for six years and global head of Roche's Mergers & Acquisition team for six years. He serves on the Board of Directors at Gritstone Bio, and previously served on the Board of Directors of Corvus Pharmaceuticals and several non-profit boards.